P-3058 Vs. MOB-015 - The great Canadian show down in nail fungus is coming and from my POV it's going to be a one-sided slaughter.
When I started monetization there was a string of 3 separate bets forming around 1 primary theme: nail fungus.
These were Cipher, Moberg, and Medexus. Two listed onto the TSX, one on the Stockholm exchange. I clearly at one point diverged away from considering Medexus a serious contender in this market early on, but I did not engage many people with people in long form content as to why. I hope that most of my readers if engaged with my writing use this as a tertiary source while they themselves go out and engage things in a way that’s not relying on what I’m saying. I think that if you do this, it probably wouldn’t have taken you long to figure out why, but you need to have asked questions yourself and then looked for an answer.
Anyways, if you’ve been following along, it’s clear at one point something changed as to what I considered the chief rival asset to face Moberg’s product. I’m going to explain why.